Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus Exemestane in Advanced ER+ Breast Cancer
NCT00767520Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2009
- Primary completion
- Mar 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 2 trial of dasatinib in breast cancer, sponsored by Bristol Myers Squibb. Started Feb 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00767520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00767520.